Vaccine Safety Registry
Varicella Vaccine Safety
Institutional safety information on varicella vaccines. Clinical data for Varivax and ProQuad, side effect profiles, and long-term surveillance metadata.
Medically reviewed by
Dr. Simran Kohli, MBBS, MD (General Medicine), DM (Infectious Diseases)
View Clinical ProfileOpen Access Clinical Intelligence for All Readers
HCP Connect provides publicly accessible vaccine-safety information for healthcare professionals, patients, caregivers, researchers, and the wider public. Access to this Vaccine Safety Monograph does not require an account, registration, or NPI verification.
Translate this vaccine safety monograph into your preferred language:
Automated translation provided for accessibility · English version is the authoritative clinical record.
Clinical Overview
Professional summary
Varicella (Chickenpox) is a highly contagious disease caused by the Varicella-Zoster Virus (VZV). While often viewed as a standard pediatric milestone, pathology can be severe in infants, adolescents, pregnant individuals, and immunocompromised cohorts.
Post-recovery, VZV maintains clinical latency within neural ganglia, posing a lifelong risk for Herpes Zoster (Shingles) reactivation. Universal immunization serves as the primary barrier to both acute infection and long-term sequelae.
Vaccine Formulations
Module specifics & formulations
Formulation Node
Varivax
Single-Antigen Protocol | Approved 1995
- Formulation: Live, attenuated VZV node.
- Authorization: Indicated for individuals 1 year and older.
- Registry Status: Single formula standard for universal use.
- Administration: Optimized for primary varicella protection.
Formulation Node
ProQuad (MMRV)
Combination Module | Approved 2005
- Composition: Measles, Mumps, Rubella, and Varicella nodes.
- Target Cohort: Optimized for pediatric subjects ages 1-12 years.
- Registry Formulations: Available in HSA and RHA frozen formats.
- Clinical Utility: Reduces injection frequency in standard schedules.
Clinical Triage
Eligibility & contraindications
Routine Protocol
- Pediatric initiation (12-15 months)
- Final booster series (4-6 years)
- Catch-up synchronization for non-immune adults
Exclusion Logic
- Gestational status (Pregnancy)
- Undiagnosed immunodeficiency
- Anaphylactic gelatin/neomycin allergy
Adverse Events
Reported reactions & surveillance
Common Reactions
- Injection site localized pain
- Pyrexia (Fever)
- Transient erythematous rash
- Joint stiffness
Serious Clinical Nodes
- Infectious rash
- Pulmonary/hepatic infection
- Meningitis
- Febrile seizures
Surveillance Analytics
Post-market surveillance metrics
1995
Registry Entry
134M+
Doses Distributed
22 Years
Consensus Review
Institutional Surveillance
Decades of surveillance and Merck's 22-year data synchronization confirm a highly favorable safety profile across all global monitored cohorts.
Editorial Governance
Clinical Reviewers & Authors
Dr. Simran Kohli
MBBS, MD (General Medicine), DM (Infectious Diseases)
Infectious Diseases
All vaccine safety monographs are authored and reviewed by credentialed medical specialists in infectious disease, immunology, and pediatrics.
Browse All Clinical Authors & Medical Reviewers DirectoryEvidence Base
Sources & References
The clinical guidance, contraindications, and safety surveillance statistics in this monograph are synthesized directly from authoritative public health agencies, regulatory package inserts, and peer-reviewed clinical studies:
- 1CDC2024Prevention of Varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Recommendations and Reports, 56(RR04):1-40
- 2WHO2024Varicella and herpes zoster vaccines: WHO position paper, June 2014
Weekly Epidemiological Record, 89(25):265-288
- 3FDA2024VARIVAX (Varicella Virus Vaccine Live) Prescribing Information & Safety Profile
U.S. Food and Drug Administration CBER, Merck & Co., Inc.
- 4Pediatrics2023A 14-Year Postlicensure Study of Varicella Vaccine Safety in Children and Adolescents
Pediatrics, 131(5):e1389-e1397 (CDC Vaccine Safety Datalink)
Cite & Reference This Monograph
Content Licensing & Governance
Content Licensing & Reuse Policy
HCP Connect. Content licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). See our Content Licensing & Reuse Policy for details.
Authored by Dr. Aditya Kumar and clinically reviewed by Dr. Simran Kohli, in alignment with HCP Connect Clinical Faculty & Reviewers Directory. Content verified against 2026 CDC ACIP and WHO SAGE safety protocols.
Vaccine Safety Enquiries & Direct Response
HCP Connect welcomes clinical questions, public health inquiries, and feedback regarding our vaccine safety monographs. Our clinical editorial staff and medical reviewers actively monitor all incoming communications.
Guaranteed Enquiry Response Timeline
We commit to responding in writing to all clinical and public enquiries within 2–3 business days (guaranteed within 5 calendar days, well within the 10 calendar day international assessment standard). Urgent clinical sourcing corrections are triaged within 24 hours.